Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Hi All,
I found the following text in Mallinckrodt 2020 Q1 earning report transcript (a link to the full copy of the text can be found at the end of this post):
According to today news release (see the link below)
The first milestone payment of $0.34/share will be by the end of this year: "...The company expects to begin recruiting by the end of 2019 for a Phase 3 clinical trial investigating MNK-6105 in patients being treated for acute HE in the hospital."
And once phase 2a of MNK-6106 to be completed by the end of Q1/2020, if the results is good, phase 3 should follow after that and we will receive the 2nd milestone payment in Q2/2020.
https://finance.yahoo.com/news/first-patient-enrolled-mallinckrodts-phase-104500633.html
As described in the clinical website: https://clinicaltrials.gov/ct2/show/NCT03712280
They're still in phase 2a for studying pharmacodynamics/safety/pharmacokinetics of oral administration MNK6106. If the clinical data comming out in the upcoming October is good, they're definitely going to start Phase 3 trial for oral MNK6106, and for this we'll receive $0.52/share as soon as the very first patient enrolled for the trial.
Below is the 3 milestone payments:
1). $0.52/share if the first patient is enrolled in a Phase 3 for oral trial MNK6106
2). $0.34/share if the first patient is enrolled in a Phase 3 for IV trial MNK6105.
3) $1.72/share if the combined sales of MNK6105 & MNK6106 worldwide exceed $500 million before 2029
BTW, below is the link to the previous Phase 2b clinical trial for Oral OCR-002 conducted by Ocera:
https://clinicaltrials.gov/ct2/show/NCT01966419
Hi All,
Just to let you know that Mallinckrodt had updated MNK-6106 study record by delaying the clinical results by 3 months; the clinical trial completion date was originally scheduled on 7/30/2019 is now moved to 10/30/2019.
Detailed info can be found via the following link:
https://clinicaltrials.gov/ct2/history/NCT03712280?A=3&B=4&C=Side-by-Side#StudyPageTop
You better check for the date before posting:
https://fintel.io/soh/us/adxs/deutsche-bank-ag-
I'd warned you guys over a year ago to sell all shares and move on when this crappy adxs was traded above $3/share (or $45/share post-split):
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=138599026
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=138599138
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=138683765
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=138685262
Just in case some of you guys are unaware about this as of 07/31/18 ADXS book value is at $33.3M. Given a burn rate of $14M/quarter, the book value will be reduced to around $5M by 01/31/19.
I think they're going to file for bankruptcy by April, 2019
Thanks, Dew.
It's still a pure speculation on your part and no one know for sure the reason for the termination. Advaxis will needs to explain this soon as or SP will fall further...
According to SEC filing, the new name for IV OCR-002 is "MNK-6105" and Oral OCR-002 is "MNK-6106"
With all the indicators so far, it's obvious that ADXS is now at the beginning of Death Spiral Financing process which will eventually wipe out all your investment within a year or twos. This garbage is worse than NWBO and will end up like NSPR and DRYS. Take a look at the the charts below to see how your investment funds will be like by 2020:
https://finance.yahoo.com/quote/NSPR?p=NSPR&.tsrc=fin-srch
https://finance.yahoo.com/quote/DRYS?p=DRYS&.tsrc=fin-srch
How have you been doing with your investment in ADXS lately???
Told you it's a garbage, but you're too dense to see it.
With the S-3 filing yesterday and institutional ownership is now dropped to 21%, this thing is going to trade under $1 by October and $0.70/share by January/19.
As I've stated many times before ADXS is going the exact same path like NWBO
$4K today and $13.5K last Friday
Sold all the shares for a quick 10% gain ($4K) today.
Still consider this as garbage and not good for long term investment.
This thing looks good today. I bought some shares this morning and plan to add more.
Ouch! sorry that very last line should not be in the message.
Just like ADXS, I'm in JCP only for short-term, and will dump all the shares once they announce new CEO.
ADXS is now back to the low $1.30s but I'm not buying any share yet. It's not a good idea for holding the garbage over the weekend.
Grabbed 30K shares @1.19 this morning...
Yes, I know ADXS is garbage but sometimes we can make money out of the garbage :)
As stated in my other post, I'm expecting ADXS will become penny stock by next February:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=138599026
It's a "Hail-Mary" filing, so the news announcement today is expected and I had tried to help your guys with the following post
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=138505946
"Given the unimpressive clinical results and the very small number of participants (less than 65), there is a high chance of the MAA getting rejected by EMU. So instead of hoping for the potential commercialization of axalimogene filolisbac, shareholders should be prepared for the possibility of the MAA rejection which will send share price under $2/share."
Q1/2018 Results Earnings Call Transcript:
https://seekingalpha.com/article/4155747-advaxis-adxs-ceo-tony-lombardo-q1-2018-results-earnings-call-transcript
Analysts questions clearly show that they're very concerning with the clinical trial on hold. I think they're going to issue downgrades in the next couple days, and share price will drop further even after the huge drop tomorrow.
Of course there is a possibility of reverse takeover, too. But with all the progress have been made so far as described under the Corporate Update session in the E/R which can be viewed via this link ), and we all know that Versartis's Somavaratan does work (as described in this article ), it's just that the drug is as effective as Pfizer's Genotropin, but Somavaratan is designed for bi-weekly treatment while Pfizer's Genotropin required daily injection, and Ascendis's TransCon designed for weekly treatment, and also Somavaratan can be stored at room temperature. Given all of this, what would be best scenario for maximizing shareholders value? THX!
The following text is from today earning release:
... said Jay Shepard, President and CEO of Versartis, Inc. “While we cannot make any assurances that a strategic transaction will be recommended by the Board, we are encouraged by the interest and opportunities we have seen and we are now at an advanced stage in our review process. Our goal remains to maximize value for all Versartis shareholders. We sincerely appreciate the patience shareholders have shown as we evaluate paths forward and we hope to provide a further update in the coming weeks.”
The texts in bold & underline clearly indicate that they're near the conclusion of the reviewing process and the decision will be announced very soon in the next couple weeks.
And the balance sheet from the latest earning report:
- Total assets: $93.78M
- Total liabilities: $11.02M
- Total stockholders' equity = $93.78M - $11.02M = $82.76M
- Total # of outstanding shares = $31.1M/$0.87 = 35.75M shares
So for the worst case scenario: company properties to be auctioned and cash distributed back to shareholders, we will receive at least $82.76M/35.75M = $2.31/share. I think the possibility for this occurred is very small and someone will pay at least $8/share to acquire VSAR.
So far 158K shares traded as high as $1.80 after the hours:
https://www.nasdaq.com/symbol/vsar/after-hours
Yes, %100 agree with you on this; we're sitting on a gold mine.
Q4 2017 E/R just came out; up by 12.58% after the hour and will trade above $2 tomorrow as the existing amount of cash after all liabilities is currently at: $49.24M + $31.1M = $80.34M. With # outstanding shares @ 35.81M share, cash/share = $80.34/35.81 = $2.24/share
https://finance.yahoo.com/news/versartis-reports-fourth-quarter-full-210500107.html
2/23/18 is simply the date the 13F was filed. The shares were actually sold months ago. Click the (up) arrow to view the report in detail.
https://fintel.io/so/us/adxs
When investors like Alex Denner (The 25 most influential people in biopharma today) dumping shares for loss, it has to be something wrong with the science.
Perhaps ADXS share price will double/or triple overnight if Advaxis simply rename their crappy/outdated LM-based immunotherapy to something like blockchain-based immunotherapy :)
Nicely done!
I think You'll be able to buy those shares back under $2.50/share before this Friday.